Names like idarucizumab, levetiracetam and ustekinumab may look like words from Greek or Norse mythology, but they're chosen with purpose ...

In order to monitor LASA (look-alike sound-alike) drugs, a suitable mechanism has to be evolved by CDSCO in coordination with SLAs. Stringent regulation needs to be in place while granting permission ...